Common Stock, par value $0.001 per share
- Symbol
- VTGN
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Vistagen Therapeutics, Inc.
VTGNNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events On September 24, 2026, Vistagen Therapeutics, Inc. (the “Company”) issued a press release summarizing positive exploratory efficacy data presented by the Company at Psych Congress 2026.…
Press release in this filing
Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder →Company context
Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of rapid-onset neurocircuitry-focused intranasal product candidates called pherines. Vistagen’s pherine product candidates are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options, if successfully developed and approved. Vistagen’s most advanced intranasal pherine product candidates are fasedienol for the acute treatment of social anxiety disorder, itruvone for treatment of major depressive disorder, and refisolone for treatment of vasomotor symptoms (hot flashes) due to menopause. Connect at www. Vistagen.com
Current securities
Recent company filings
Registered securities in this filing
Vistagen Therapeutics, Inc. · 8-K · Filed 2026-09-24
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events
On September 24, 2026, Vistagen Therapeutics, Inc. (the “Company”) issued a press release summarizing positive exploratory efficacy data presented by the Company at Psych Congress 2026. The poster highlights a potential efficacy signal for fasedienol nasal spray, the Company's rapid-onset Phase 3 product candidate, observed in two different double-blind, placebo-controlled public speaking challenge studies involving participants with very severe social anxiety disorder, as defined by the Liebowitz Social Anxiety Scale (“LSAS”). A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.